Oligonucleotide Therapeutics: From Scientific Concept to a Clinically Validated Drug Modality
核心洞察
Oligonucleotide therapeutics (搜索) modulate gene expression through Watson-Crick base pairing with complementary RNA/DNA sequences, establishing a clinically validated drug modality across multiple indications.
Since the first FDA approval in 1998, 24 oligonucleotide drugs—including ASOs, siRNAs, and aptamers—have received FDA approval.
This clinical success was enabled by decades of advancements in oligonucleotide chemistry that optimized stability, potency, biodistribution, and safety.
Oligonucleotide therapeutics (搜索) have evolved from a scientific concept into a clinically validated drug modality across multiple indications. Their therapeutic premise lies in their ability to modulate gene expression through Watson-Crick base pairing with complementary RNA/DNA sequences.
Since the first FDA approval in 1998, 24 oligonucleotide drugs—including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers—have received FDA approval. This clinical success was enabled by decades of advancements in oligonucleotide chemistry to optimize stability, potency, biodistribution, and safety.
A Maturing Therapeutic Modality
The oligonucleotide field has progressed substantially since its inception, transitioning from an experimental concept to a validated approach with broad clinical application. The mechanism of action is rooted in the fundamental principle of Watson-Crick base pairing, which allows these molecules to selectively bind complementary RNA or DNA sequences and thereby modulate gene expression.
The diversity of approved agents reflects the versatility of the platform. ASOs, siRNAs, and aptamers each represent distinct structural and mechanistic classes within the oligonucleotide family, and together they have demonstrated therapeutic utility across multiple indications.
Chemistry as the Enabling Foundation
The clinical translation of oligonucleotide therapeutics (搜索) has depended heavily on advances in medicinal chemistry. Decades of iterative improvements in oligonucleotide chemistry have addressed key challenges that historically limited the therapeutic potential of these molecules, including stability, potency, biodistribution, and safety.
These chemical optimizations have been central to overcoming the barriers that once constrained oligonucleotide-based approaches, enabling the 24 FDA approvals achieved to date and solidifying the modality's position within the pharmaceutical landscape.